• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

硫酸伊沙康唑在儿科肿瘤和干细胞移植人群中的使用和疗效特征：单机构回顾性研究。

Characterization of the Use and Efficacy of Isavuconazonium Sulfate in a Pediatric Oncology and Stem Cell Transplant Population: A Single Institution Retrospective Review.

机构信息

Department of Pharmacy.

Department of Medicine, Infectious Diseases Service.

出版信息

J Pediatr Hematol Oncol. 2024 Mar 1;46(2):e143-e146. doi: 10.1097/MPH.0000000000002812. Epub 2024 Jan 17.

DOI:10.1097/MPH.0000000000002812
PMID:38237014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11881917/
Abstract

Isavuconazonium sulfate (ISA) is a triazole antifungal approved for the treatment of invasive aspergillosis and mucormycosis in adults. This single-center, retrospective review of pediatric oncology and stem cell transplant patients receiving ISA for prophylaxis (n=20) or treatment (n=6) of invasive fungal disease (IFD) aims to characterize real-world clinical efficacy and toxicity of ISA in patients <18 years of age. Of 20 patients receiving ISA for prophylaxis, three patients had presumed breakthrough IFD (1 proven, 2 probable/possible). No adverse effects were attributed to ISA use or led to the discontinuation of therapy.

摘要

硫酸伊沙康唑（ISA）是一种三唑类抗真菌药物，批准用于治疗成人侵袭性曲霉病和毛霉病。本单中心回顾性研究纳入了接受 ISA 预防（n=20）或治疗（n=6）侵袭性真菌病（IFD）的儿科肿瘤和干细胞移植患者，旨在评估 ISA 在<18 岁患者中的真实世界临床疗效和毒性。在接受 ISA 预防的 20 例患者中，3 例患者疑似发生了 IFD 突破（1 例确诊，2 例可能/很可能）。无不良事件归因于 ISA 使用或导致治疗中断。

相似文献

1
Characterization of the Use and Efficacy of Isavuconazonium Sulfate in a Pediatric Oncology and Stem Cell Transplant Population: A Single Institution Retrospective Review.硫酸伊沙康唑在儿科肿瘤和干细胞移植人群中的使用和疗效特征：单机构回顾性研究。
J Pediatr Hematol Oncol. 2024 Mar 1;46(2):e143-e146. doi: 10.1097/MPH.0000000000002812. Epub 2024 Jan 17.
2
Clinical research advances of isavuconazole in the treatment of invasive fungal diseases.伊曲康唑治疗侵袭性真菌病的临床研究进展。
Front Cell Infect Microbiol. 2022 Dec 1;12:1049959. doi: 10.3389/fcimb.2022.1049959. eCollection 2022.
3
Experience with isavuconazole in the treatment of mucormycosis and breakthrough fungal infections.艾沙康唑治疗毛霉菌病和突破性真菌感染的经验。
Rev Iberoam Micol. 2025 Jan-Mar;42(1):51-54. doi: 10.1016/j.riam.2025.01.005. Epub 2025 Mar 21.
4
Impact of current clinical guidelines on the management of invasive fungal disease.当前临床指南对侵袭性真菌病管理的影响
Rev Iberoam Micol. 2025 Jan-Mar;42(1):15-21. doi: 10.1016/j.riam.2025.02.002. Epub 2025 Mar 22.
5
Development and validation of a risk model for identification of non-neutropenic, critically ill adult patients at high risk of invasive Candida infection: the Fungal Infection Risk Evaluation (FIRE) Study.开发和验证一种风险模型，用于识别非中性粒细胞减少、危重症成年患者侵袭性念珠菌感染的高危人群：真菌感染风险评估（FIRE）研究。
Health Technol Assess. 2013 Feb;17(3):1-156. doi: 10.3310/hta17030.
6
Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.伏立康唑与两性霉素B或氟康唑用于中性粒细胞减少的癌症患者的比较
Cochrane Database Syst Rev. 2014 Feb 24;2014(2):CD004707. doi: 10.1002/14651858.CD004707.pub3.
7
Pre-emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer.癌症患者中性粒细胞减少伴发热时的抢先性抗真菌治疗与经验性抗真菌治疗。
Cochrane Database Syst Rev. 2022 Nov 28;11(11):CD013604. doi: 10.1002/14651858.CD013604.pub2.
8
Real-world use of isavuconazole in adult oncohematology patients.艾沙康唑在成人肿瘤血液学患者中的实际应用。
Rev Iberoam Micol. 2025 Jan-Mar;42(1):22-25. doi: 10.1016/j.riam.2025.02.001. Epub 2025 Mar 19.
9
Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.用于预防非中性粒细胞减少的重症患者真菌感染的抗真菌药物。
Cochrane Database Syst Rev. 2016 Jan 16;2016(1):CD004920. doi: 10.1002/14651858.CD004920.pub3.
10
Real-life experience on the use of isavuconazole in solid organ transplantation.在实体器官移植中使用艾沙康唑的实际经验。
Rev Iberoam Micol. 2025 Jan-Mar;42(1):26-31. doi: 10.1016/j.riam.2025.02.004. Epub 2025 Apr 4.

引用本文的文献

1
Incidence of Breakthrough Fungal Infections in Patients With Isavuconazole Prophylaxis: A Systematic Review and Meta-analysis.接受艾沙康唑预防治疗的患者中突破性真菌感染的发生率：一项系统评价和荟萃分析。
Open Forum Infect Dis. 2025 Mar 14;12(4):ofaf163. doi: 10.1093/ofid/ofaf163. eCollection 2025 Apr.

本文引用的文献

1
Isavuconazonium Sulfate Use in Multi-Modal Management of Invasive Mucormycosis in Four Pediatric Allogeneic Hematopoietic Cell Transplant Patients.硫酸艾沙康唑在4例儿科异基因造血细胞移植患者侵袭性毛霉病多模式管理中的应用
J Pediatr Pharmacol Ther. 2021;26(8):863-867. doi: 10.5863/1551-6776-26.8.863. Epub 2021 Nov 10.
2
Evaluation of Posaconazole Dosing in Children and Young Adults: A Single-Center Review.儿童和青年成人泊沙康唑给药剂量的评估：一项单中心回顾
J Pediatr Pharmacol Ther. 2021;26(8):834-840. doi: 10.5863/1551-6776-26.8.834. Epub 2021 Nov 10.
3
Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.伊曲康唑与伏立康唑作为异基因造血细胞移植受者一线抗真菌预防治疗的疗效和安全性比较。
Med Mycol. 2021 Oct 4;59(10):970-979. doi: 10.1093/mmy/myab025.
4
Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients.静脉和口服硫酸异帕米星在儿科患者中的安全性、耐受性和群体药代动力学。
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0029021. doi: 10.1128/AAC.00290-21.
5
Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience.伊曲康唑预防和治疗侵袭性真菌感染：单中心经验。
Transpl Infect Dis. 2021 Apr;23(2):e13469. doi: 10.1111/tid.13469. Epub 2020 Nov 4.
6
Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients.儿童恶性肿瘤患者和造血干细胞移植受者全身性抗真菌预防的临床实践指南。
J Clin Oncol. 2020 Sep 20;38(27):3205-3216. doi: 10.1200/JCO.20.00158. Epub 2020 May 27.
7
Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.艾沙康唑作为急性髓系白血病或骨髓增生异常综合征患者的主要抗真菌预防用药：一项开放标签、前瞻性、2期研究。
Clin Infect Dis. 2021 May 18;72(10):1755-1763. doi: 10.1093/cid/ciaa358.
8
Safety of Isavuconazonium Sulfate in Pediatrics Patients With Hematologic Malignancies and Hematopoietic Cell Transplantation With Invasive Fungal Infections: A Real World Experience.硫酸艾沙康唑在患有血液系统恶性肿瘤和接受造血细胞移植并伴有侵袭性真菌感染的儿科患者中的安全性：一项真实世界经验。
J Pediatr Hematol Oncol. 2020 May;42(4):261-265. doi: 10.1097/MPH.0000000000001787.
9
A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.一项关于异氟康唑预防异基因造血细胞移植患者侵袭性真菌感染的单中心开放标签试验。
Biol Blood Marrow Transplant. 2020 Jun;26(6):1195-1202. doi: 10.1016/j.bbmt.2020.02.009. Epub 2020 Feb 20.
10
A Case Series and Literature Review of Isavuconazole Use in Pediatric Patients with Hemato-oncologic Diseases and Hematopoietic Stem Cell Transplantation.儿童血液肿瘤疾病和造血干细胞移植患者应用伊曲康唑的病例系列及文献复习。
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.01783-19.